Výsledky vyhledávání - "Jan H. G. Jonkman"

Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge

Autor: Thomas Meinicke, Henrieke de Bruin, Jan J. van Lier, Joachim Stangier, Pauline N. M. Van Heiningen, W.J Tamminga, Chung‐An P. F. Su, Jan H. G. Jonkman

Publikováno v: Journal of Cardiovascular Pharmacology. 38:672-685

Telmisartan is a new angiotensin receptor antagonist possessing potent, selective, and insurmountable inhibitory activity specific to the angiotensin II type 1 (AT 1 ) receptor. The current study was performed to determine the inhibition of the angio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec233a175038d61c66576130a0d3ac60
https://doi.org/10.1097/00005344-200111000-00004

Zobrazit plný text záznamu

Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [ 14 C]Telmisartan in Healthy Volunteers

Autor: Sjoerd P. van Marle, Frans A. E. Sollie, Jochen Schmid, Heinz Switek, Aalt Verhagen, Jan H. G. Jonkman, W.J Tamminga, Dietrich Türck, Pierre Peeters, Joachim Stangier

Publikováno v: The Journal of Clinical Pharmacology. 40:1312-1322

The study was conducted in healthy male volunteers to evaluate the absorption, metabolic pattern, and mode of elimination of telmisartan, a nonpeptide angiotensin II receptor antagonist. [14C]telmisartan was administered orally in solution as a singl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::15b8d6073dee3364a1a059aa6073c85f
https://doi.org/10.1177/009127000004001202

Zobrazit plný text záznamu

Steady‐State Pharmacodynamics and Pharmacokinetics of Warfarin in the Presence and Absence of Telmisartan in Healthy Male Volunteers

Autor: Frans A. E. Sollie, B. Oosterhuis, Chung‐An P. F. Su, Jan H. G. Jonkman, Jan J. van Lier, Maarten G. C. Hendriks, Joachim Stangier

Publikováno v: The Journal of Clinical Pharmacology. 40:1331-1337

The effects of multiple-dose telmisartan on the steady-state pharmacodynamics and pharmacokinetics of warfarin were assessed in 12 healthy young males in an open-label, single-period study conducted over 30 days. Subjects received loading doses of or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a82d46e0c009d5ad7e13a671ced964a5
https://doi.org/10.1177/009127000004001204

Zobrazit plný text záznamu

The Effect of Telmisartan on the Steady‐State Pharmacokinetics of Digoxin in Healthy Male Volunteers

Autor: Jan J. van Lier, B. Oosterhuis, Joachim Stangier, Frans A. E. Sollie, Chung‐An P. F. Su, Jan H. G. Jonkman, Maarten G. C. Hendriks

Publikováno v: The Journal of Clinical Pharmacology. 40:1373-1379

A multiple-dose, open-label, two-period, crossover randomized study was conducted in 12 healthy male volunteers to investigate the effect of multiple-dose telmisartan on the steady-state pharmacokinetics of digoxin. On day 1 of a 7-day medication per

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4f4d6f7b4d2c85efb9c0bcbcb286890b
https://doi.org/10.1177/009127000004001209

Zobrazit plný text záznamu

Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male Volunteers

Autor: Sjoerd P. van Marle, Gérard Hopfgartner, Herwig Eggers, Cornelia Weber, Jan H. G. Jonkman, Henk W. Viischer, Joseph Meyer, Rita Schmitt, Herbert Birnboeck

Publikováno v: Journal of clinical pharmacology, Vol. 39, No 7 (1999) pp. 703-714

The multiple-dose pharmacokinetics, safety, and tolerability of oral bosentan, a selective endothelin receptor antagonist, were investigated in healthy male volunteers. In study A, an ascending-dose, double-blind, placebo-controlled trial, doses of 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd6d2e22be897556ce42d871520f0d5
https://doi.org/10.1177/00912709922008344

Zobrazit plný text záznamu

Absorption and mass balance of piperonyl butoxide following an 8-h dermal exposure in human volunteers

Autor: Karl L. Gabriel, Jan H. G. Jonkman, Frederick J. Preiss, Sami Selim, Tom G. Osimitz

Publikováno v: Toxicology Letters. 107:207-217

Dermal absorption, metabolism and excretion of piperonyl butoxide (PBO) was studied using 14C-PBO either by itself as a 3% (w/w) solution in isopropyl alcohol or as a 4% (w/w) solution in an aqueous end-use formulation. Each of these two formulations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071916a29f42122e439caa3f0f9a9a5b
https://doi.org/10.1016/s0378-4274(99)00049-1

Zobrazit plný text záznamu

A Comparison of the Pharmacokinetics and Tolerability of Riluzole after Repeat Dose Administration in Healthy Elderly and Young Volunteers

Autor: E. Groen, G. Montay, C. Guimart, S. Kirkesseli, J. Wemer, Jan H. G. Jonkman, J.-Y. Gautier, A. Le Liboux, P. A. M. Peeters, J.-P. Cachia

Publikováno v: The Journal of Clinical Pharmacology. 39:480-486

The pharmacokinetics and tolerability of the novel antiexcitatory agent, riluzole, were compared in 18 healthy elderly and 18 healthy gender- and weight-matched young volunteers. All participants received riluzole 50 mg twice daily (the recommended d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ccf5758a24d6c189cef81e15afe144d
https://doi.org/10.1177/009127009903900507

Zobrazit plný text záznamu

Troglitazone has no effect on red cell mass or other erythropoietic parameters

Autor: P. Dogterom, S. P. van Marle, J. Wemer, L. Squassante, M. M. R. Young, Jan H. G. Jonkman

Publikováno v: European Journal of Clinical Pharmacology. 55:101-104

Objective: Troglitazone is a new anti-diabetic agent for the treatment of type 2 diabetes. In placebo-controlled trials troglitazone improves glycaemic control, reduces hyperinsulinaemia and has beneficial effects on blood lipids. However, minor, rev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80c4a72387bf2029662e2b05049687ee
https://doi.org/10.1007/s002280050602

Zobrazit plný text záznamu

Absorption and Mass Balance of MGK 264 Alone and MGK 264 Formulated with N,N-Diethyl-m-Toluamide (DEET) and MGK 326 Following an 8 H Dermal Exposure in Human Volunteers

Autor: Sami Selim, Karl L. Gabriel, Jan H. G. Jonkman, Frederick J. Preiss

Publikováno v: Journal of Toxicology: Cutaneous and Ocular Toxicology. 18:325-340

Dermal absorption, metabolism, and excretion of MGK 264 (N-octylbicycloheptene dicarboximide; McLaughlin Gormley King Company, Minneapolis, MN) was studied using [14C] MGK 264 either by itself or formulated with DEET (N,N-diethyl-m-toluamide) and MGK

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51016e8b3c339cf5b80aaf7e5b55a25b
https://doi.org/10.3109/15569529909065549

Zobrazit plný text záznamu

The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers

Autor: John Allanson, Deborah A. Smith, Richard Peck, Nanco R. Hefting, Jan J. van Lier, Emma J. Seaber, Frans A. E. Sollie, Johan Wemer, Jan H. G. Jonkman

Publikováno v: British Journal of Clinical Pharmacology. 46:433-439

Aims Zolmitriptan (Zomig (formerly 311C90)) is a novel 5-HT1B/1D receptor agonist developed for the acute oral treatment of migraine. A highly sensitive LCMS-MS assay has been developed which allows quantification of plasma concentrations of zolmitri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20e6deefe44da66cfe877a91e5a5f66b
https://doi.org/10.1046/j.1365-2125.1998.00809.x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání